Related Experiment Videos
Banisterine and Parkinson's disease
1Department of Neurology, University of Miami School of Medicine, Florida.
Clinical Neuropharmacology
|October 1, 1991
Summary
Early research explored banisterine, a harmala alkaloid, for Parkinson's disease (PD). This compound, later identified as harmine, was the first monoamine oxidase (MAO) inhibitor used therapeutically.
Area of Science:
- Pharmacology
- Neuroscience
- Medical History
Background:
- Historical use of Banisteria Caapi for Parkinson's disease (PD) reported by Louis Lewin.
- Banisterine, a psychoactive compound from Banisteria Caapi, was identified as harmine.
- Harmine was later discovered to be a reversible monoamine oxidase (MAO) inhibitor.
Purpose of the Study:
- To review the historical use of banisterine in treating parkinsonism.
- To highlight the early role of psychoactive compounds in PD therapy.
- To illustrate how early drug discoveries contribute to understanding PD pathophysiology.
Main Methods:
- Historical literature review.
- Analysis of early reports on banisterine's therapeutic use.
- Examination of the chemical and pharmacological characterization of harmala alkaloids.
Main Results:
- Banisterine was the first monoamine oxidase (MAO) inhibitor used for parkinsonism.
- Initial reports in 1929 generated significant public interest, dubbing banisterine a "magic drug."
- Therapeutic interest in harmala alkaloids waned during the 1930s despite ongoing research.
Conclusions:
- The historical use of banisterine demonstrates the early impact of psychoactive substances on PD treatment development.
- The story of banisterine underscores its significance as the first MAO inhibitor applied to parkinsonism.
- Understanding historical therapeutic agents aids in elucidating the pathophysiology of Parkinson's disease.